CTOs on the Move

Pharmaceutics International

www.pharm-int.com

 
Pharmaceutics International, Inc. (Pii) is a US-based contract development and manufacturing organization (CDMO) with a passion for solving problems. Pii`s Hunt Valley, Maryland, campus includes 70 manufacturing suites with four integrated aseptic filling lines. We offer contract analytical development and support formulation and manufacturing of oral solid dosage forms. Our professionals have extensive experience with small and large molecule compounds, developing and manufacturing complex parenteral drugs, extended-release formulations, non-aqueous injectable drug products, lyophilization, and DEA scheduled drugs.
  • Number of Employees: 250-1000
  • Annual Revenue: $100-250 Million

Executives

Name Title Contact Details
James Drob
Head of Aseptic Manufacturing, Accomplished in Technical Operations and Technical Transfer Profile

Funding

Pharmaceutics International raised $10M on 06/04/2021

Similar Companies

Novartis

Novartis provides healthcare solutions that improve and extend people`s lives. We use science-based innovation to address some of society`s most challenging healthcare issues. We discover and develop breakthrough treatments and find new ways to deliver them to as many people as possible. Our company is focused on industry-leading divisions with innovation power and global scale: pharmaceuticals, eye care and generic medicines Novartis is headquartered in Basel, Switzerland. Novartis Group companies employ approximately 120,000 associates and its products are available in more than 180 countries around the world.

Warner Chilcott

Warner Chilcott is a Rockaway, NJ-based company in the Healthcare, Pharmaceuticals, and Biotech sector.

Allen and Alice Stokes Nature

Allen and Alice Stokes Nature is a Logan, UT-based company in the Healthcare, Pharmaceuticals, and Biotech sector.

Savara Pharmaceuticals

Savara Inc. is an orphan lung disease company. Savara`s pipeline comprises: Molgradex, an inhaled granulocyte-macrophage colony-stimulating factor, or GM-CSF, in Phase 3 development for PAP, and in Phase 2a development for NTM lung infection; and AeroVanc, a Phase 3 stage inhaled vancomycin for treatment of MRSA infection in cystic fibrosis. Savara`s strategy involves expanding its pipeline of potentially best-in-class products through indication expansion, strategic development partnerships and product acquisitions, with the goal of becoming a leading company in its field. Savara`s management team has significant experience in orphan drug development and pulmonary medicine, in identifying unmet needs, developing and acquiring new product candidates, and effectively advancing them to approvals and commercialization.

Salience Learning

We are Salience Learning. We help solve life science’s most complex business challenges by delivering transformative learning experiences.